

Bruce A C Cree,, Mas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1287737/publications.pdf>

Version: 2024-02-01

199
papers

22,886
citations

15880

67
h-index

10129

145
g-index

210
all docs

210
docs citations

210
times ranked

23351
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. <i>Nature</i> , 2011, 476, 214-219.	13.7	2,400
2	Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study. <i>New England Journal of Medicine</i> , 2007, 357, 851-862.	13.9	1,529
3	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. <i>Nature Genetics</i> , 2013, 45, 1353-1360.	9.4	1,213
4	Neuromyelitis optica, psychiatric symptoms and primary polydipsia: a case report. <i>General Hospital Psychiatry</i> , 2010, 32, 648.e5-648.e8.	1.2	953
5	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. <i>Science</i> , 2019, 365, .	6.0	710
6	Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10713-10718.	3.3	709
7	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet, The</i> , 2018, 391, 1263-1273.	6.3	684
8	An open label study of the effects of rituximab in neuromyelitis optica. <i>Neurology</i> , 2005, 64, 1270-1272.	1.5	607
9	Treatment of Neuromyelitis Optica With Rituximab. <i>Archives of Neurology</i> , 2008, 65, 1443.	4.9	445
10	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. <i>Lancet, The</i> , 2019, 394, 1352-1363.	6.3	433
11	Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. <i>Human Molecular Genetics</i> , 2009, 18, 767-778.	1.4	419
12	Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. <i>Neurology</i> , 2018, 90, 777-788.	1.5	406
13	Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2016, 387, 1075-1084.	6.3	379
14	Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. <i>Lancet, The</i> , 2017, 390, 2481-2489.	6.3	377
15	Treatment of Multiple Sclerosis: A Review. <i>American Journal of Medicine</i> , 2020, 133, 1380-1390.e2.	0.6	374
16	Long-term evolution of multiple sclerosis disability in the treatment era. <i>Annals of Neurology</i> , 2016, 80, 499-510.	2.8	331
17	Mapping Multiple Sclerosis Susceptibility to the HLA-DR Locus in African Americans. <i>American Journal of Human Genetics</i> , 2004, 74, 160-167.	2.6	311
18	Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. <i>Annals of Neurology</i> , 2012, 72, 53-64.	2.8	281

#	ARTICLE	IF	CITATIONS
19	Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. <i>Human Molecular Genetics</i> , 2006, 15, 2813-2824.	1.4	279
20	Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. <i>Neurology</i> , 2004, 63, 2039-2045.	1.5	275
21	Silent progression in disease activity-free relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2019, 85, 653-666.	2.8	265
22	A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility. <i>Nature Genetics</i> , 2005, 37, 1113-1118.	9.4	243
23	Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 4777-4782.	3.3	238
24	Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 18680-18685.	3.3	231
25	Inclusion of brain volume loss in a revised measure of "no evidence of disease activity" (NEDA-4) in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1297-1305.	1.4	228
26	Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. <i>Neurology</i> , 2011, 76, 686-692.	1.5	225
27	B cell exchange across the blood-brain barrier in multiple sclerosis. <i>Journal of Clinical Investigation</i> , 2012, 122, 4533-4543.	3.9	211
28	Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. <i>Lancet Neurology</i> , The, 2014, 13, 257-267.	4.9	194
29	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <i>Lancet Neurology</i> , The, 2019, 18, 1009-1020.	4.9	191
30	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <i>Lancet Neurology</i> , The, 2019, 18, 1021-1033.	4.9	184
31	Reduction of CD8 ⁺ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e76.	3.1	171
32	MS disease activity in RESTORE. <i>Neurology</i> , 2014, 82, 1491-1498.	1.5	166
33	Rituximab before and during pregnancy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e453.	3.1	159
34	Spinal cord gray matter atrophy correlates with multiple sclerosis disability. <i>Annals of Neurology</i> , 2014, 76, 568-580.	2.8	158
35	Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review. <i>PLoS ONE</i> , 2016, 11, e0154335.	1.1	156
36	Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. <i>Brain</i> , 2009, 132, 250-259.	3.7	154

#	ARTICLE	IF	CITATIONS
37	Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis. <i>Neurotherapeutics</i> , 2017, 14, 835-841.	2.1	141
38	Disease Activity Free Status. <i>JAMA Neurology</i> , 2014, 71, 269.	4.5	132
39	Gut microbiota-specific IgA B cells traffic to the CNS in active multiple sclerosis. <i>Science Immunology</i> , 2020, 5, .	5.6	132
40	Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. <i>JAMA Neurology</i> , 2019, 76, 1359.	4.5	129
41	Neuromyelitis Optica. <i>Seminars in Neurology</i> , 2002, 22, 105-122.	0.5	128
42	Gut microbiome analysis in neuromyelitis optica reveals overabundance of <i>Clostridium perfringens</i> . <i>Annals of Neurology</i> , 2016, 80, 443-447.	2.8	125
43	Progressive multifocal leukoencephalopathy after fingolimod treatment. <i>Neurology</i> , 2018, 90, e1815-e1821.	1.5	123
44	Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. <i>Neurology</i> , 2008, 71, 1390-1395.	1.5	119
45	A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 22932-22943.	3.3	119
46	Continuous daily assessment of multiple sclerosis disability using remote step count monitoring. <i>Journal of Neurology</i> , 2017, 264, 316-326.	1.8	109
47	Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci. <i>Human Molecular Genetics</i> , 2010, 19, 953-962.	1.4	108
48	Natalizumab dosage suspension: Are we helping or hurting?. <i>Annals of Neurology</i> , 2010, 68, 395-399.	2.8	108
49	Microcystic Inner Nuclear Layer Abnormalities and Neuromyelitis Optica. <i>JAMA Neurology</i> , 2013, 70, 629.	4.5	107
50	Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis. <i>Neurology</i> , 2018, 90, 789-800.	1.5	107
51	Characterizing the Mechanisms of Progression in Multiple Sclerosis. <i>Archives of Neurology</i> , 2005, 62, 1345.	4.9	105
52	Uncoupling the Roles of HLA-DRB1 and HLA-DRB5 Genes in Multiple Sclerosis. <i>Journal of Immunology</i> , 2008, 181, 5473-5480.	0.4	105
53	Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 1002-1005.	0.9	103
54	Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 97, 378-388.	1.5	100

#	ARTICLE	IF	CITATIONS
55	Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. Archives of Neurology, 2009, 66, 226-33.	4.9	92
56	Acute Transverse Myelitis: Demyelinating, Inflammatory, and Infectious Myelopathies. Seminars in Neurology, 2012, 32, 097-113.	0.5	91
57	Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Annals of Neurology, 2010, 68, 145-150.	2.8	90
58	In vivo evidence of glutamate toxicity in multiple sclerosis. Annals of Neurology, 2014, 76, 269-278.	2.8	88
59	Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients. JCI Insight, 2017, 2, .	2.3	84
60	Clemastine rescues myelination defects and promotes functional recovery in hypoxic brain injury. Brain, 2018, 141, 85-98.	3.7	83
61	Quantification and Functional Characterization of Antibodies to Native Aquaporin 4 in Neuromyelitis Optica. Archives of Neurology, 2010, 67, 1201-8.	4.9	82
62	Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls. Human Molecular Genetics, 2013, 22, 4194-4205.	1.4	81
63	Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis. JAMA Neurology, 2015, 72, 897.	4.5	78
64	Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. Journal of Clinical Neuroscience, 2011, 18, 997-998.	0.8	77
65	Response to Interferon Beta-1a Treatment in African American Multiple Sclerosis Patients. Archives of Neurology, 2005, 62, 1681.	4.9	76
66	Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies. Neurology: Genetics, 2016, 2, e87.	0.9	76
67	Disease-modifying therapies alter gut microbial composition in MS. Neurology: Neuroimmunology and Neuroinflammation, 2019, 6, e517.	3.1	75
68	Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Current Opinion in Neurology, 2019, 32, 365-377.	1.8	73
69	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. Annals of Neurology, 2021, 89, 895-910.	2.8	72
70	Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. Journal of Allergy and Clinical Immunology, 2005, 116, 453-459.	1.5	70
71	IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci. Genes and Immunity, 2010, 11, 397-405.	2.2	70
72	Association of Continuous Assessment of Step Count by Remote Monitoring With Disability Progression Among Adults With Multiple Sclerosis. JAMA Network Open, 2019, 2, e190570.	2.8	69

#	ARTICLE	IF	CITATIONS
73	Vitamin D in African Americans with multiple sclerosis. <i>Neurology</i> , 2011, 76, 1824-1830.	1.5	67
74	Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. <i>Neurology</i> , 2017, 89, 1584-1593.	1.5	65
75	A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis. <i>Nature Communications</i> , 2019, 10, 2236.	5.8	65
76	Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. <i>Neurology</i> , 2009, 72, 1760-1765.	1.5	64
77	Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 835-843.	1.4	64
78	Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple Sclerosis. <i>JAMA Neurology</i> , 2016, 73, 795.	4.5	64
79	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2020, 19, 988-997.	4.9	64
80	Siponimod and Cognition in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 96, e376-e386.	1.5	64
81	Placebo-controlled study in neuromyelitis optica—Ethical and design considerations. <i>Multiple Sclerosis Journal</i> , 2016, 22, 862-872.	1.4	63
82	Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014, 1, e34.	3.1	61
83	Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. <i>Journal of Neurology</i> , 2019, 266, 1182-1193.	1.8	61
84	Linkage and association with the NOS2A locus on chromosome 17q11 in multiple sclerosis. <i>Annals of Neurology</i> , 2004, 55, 793-800.	2.8	60
85	A Major Histocompatibility Class I Locus Contributes to Multiple Sclerosis Susceptibility Independently from HLA-DRB1*15:01. <i>PLoS ONE</i> , 2010, 5, e11296.	1.1	60
86	An ImmunoChip study of multiple sclerosis risk in African Americans. <i>Brain</i> , 2015, 138, 1518-1530.	3.7	60
87	Rituximab in neurological disease: principles, evidence and practice. <i>Practical Neurology</i> , 2019, 19, 5-20.	0.5	59
88	Magnetic Resonance Spectroscopy Markers of Disease Progression in Multiple Sclerosis. <i>JAMA Neurology</i> , 2014, 71, 840.	4.5	57
89	Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2010, 292, 28-35.	0.3	56
90	Multiple Sclerosis-Associated Changes in the Composition and Immune Functions of Spore-Forming Bacteria. <i>MSystems</i> , 2018, 3, .	1.7	56

#	ARTICLE	IF	CITATIONS
91	Neuromyelitis optica: Diagnosis, pathogenesis, and treatment. <i>Current Neurology and Neuroscience Reports</i> , 2008, 8, 427-433.	2.0	54
92	Genetic risk variants in African Americans with multiple sclerosis. <i>Neurology</i> , 2013, 81, 219-227.	1.5	54
93	The Gut Microbiome in Neuromyelitis Optica. <i>Neurotherapeutics</i> , 2018, 15, 92-101.	2.1	54
94	Precision medicine in chronic disease management: The multiple sclerosis <sc>B</sc> <sc>io</sc> <sc>S</sc> <sc>creen</sc>. <i>Annals of Neurology</i> , 2014, 76, 633-642.	2.8	53
95	Multifactor dimensionality reduction reveals gene-gene interactions associated with multiple sclerosis susceptibility in African Americans. <i>Genes and Immunity</i> , 2006, 7, 310-315.	2.2	52
96	Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy. <i>PLoS ONE</i> , 2011, 6, e16664.	1.1	51
97	Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1526-1534.	1.4	49
98	Neuromyelitis optica following human papillomavirus vaccination. <i>Neurology</i> , 2012, 79, 285-287.	1.5	47
99	Emerging Monoclonal Antibody Therapies for Multiple Sclerosis. <i>Neurologist</i> , 2006, 12, 171-178.	0.4	44
100	Multiple sclerosis genetics. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 122, 193-209.	1.0	44
101	Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays. <i>Neurology</i> , 2006, 67, 176-177.	1.5	41
102	Ovarian aging is associated with gray matter volume and disability in women with MS. <i>Neurology</i> , 2018, 90, e254-e260.	1.5	41
103	Telomere Length Is Associated with Disability Progression in Multiple Sclerosis. <i>Annals of Neurology</i> , 2019, 86, 671-682.	2.8	41
104	Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 429-440.	1.4	40
105	Challenges and opportunities in designing clinical trials for neuromyelitis optica. <i>Neurology</i> , 2015, 84, 1805-1815.	1.5	39
106	Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 268-281.	2.8	39
107	Efficacy of Natalizumab Therapy in Patients of African Descent With Relapsing Multiple Sclerosis. <i>Archives of Neurology</i> , 2011, 68, 464.	4.9	38
108	Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis. <i>Annals of Neurology</i> , 2018, 84, 51-63.	2.8	38

#	ARTICLE	IF	CITATIONS
109	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1255-1262.	1.4	37
110	Therapeutic Considerations for Disease Progression in Multiple Sclerosis. <i>Archives of Neurology</i> , 2005, 62, 1519-30.	4.9	36
111	Refining the association of MHC with multiple sclerosis in African Americans. <i>Human Molecular Genetics</i> , 2010, 19, 3080-3088.	1.4	35
112	Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e272.	3.1	31
113	Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. <i>BMC Neurology</i> , 2014, 14, 220.	0.8	30
114	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. <i>Neurology</i> , 2020, 95, e1027-e1040.	1.5	28
115	Transient hyperckemia in the setting of neuromyelitis optica (NMO). <i>Muscle and Nerve</i> , 2014, 50, 859-862.	1.0	27
116	Encephalitis of Unclear Origin Diagnosed by Brain Biopsy. <i>JAMA Neurology</i> , 2015, 72, 66.	4.5	26
117	MOG transmembrane and cytoplasmic domains contain highly stimulatory T-cell epitopes in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014, 1, e20.	3.1	24
118	Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 366-379.	1.4	24
119	Acute inflammatory myelopathies. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 122, 613-667.	1.0	23
120	Onset of secondary progressive <sc>MS</sc> after long-term rituximab therapy – a case report. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 46-52.	1.7	22
121	Phase IV study of retention on fingolimod <i>versus</i> injectable multiple sclerosis therapies: a randomized clinical trial. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641877433.	1.5	22
122	Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	22
123	Longitudinally persistent cerebrospinal fluid B-cells can resist treatment in multiple sclerosis. <i>JCI Insight</i> , 2019, 4, .	2.3	22
124	Acute transverse myelitis: Is the "idiopathic" form vanishing?. <i>Neurology</i> , 2005, 65, 1857-1858.	1.5	21
125	Harnessing electronic medical records to advance research on multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 408-418.	1.4	21
126	Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. <i>Journal of Neurology</i> , 2015, 262, 326-336.	1.8	20

#	ARTICLE	IF	CITATIONS
127	Prognostic biomarkers of IFN β therapy in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2015, 21, 894-904.	1.4	20
128	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102673.	0.9	20
129	Disability Outcomes in the N-MOMentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	20
130	SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1485-1498.	1.4	19
131	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 51, 102844.	0.9	19
132	Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOMentum Study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103352.	0.9	19
133	Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5% years. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1591-1605.	1.4	19
134	pRNFL as a marker of disability worsening in the medium/long term in patients with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e533.	3.1	18
135	COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab. <i>Neurology and Therapy</i> , 2022, 11, 741-758.	1.4	18
136	The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis. <i>CNS Drugs</i> , 2022, 36, 703-719.	2.7	18
137	Genetics of primary progressive multiple sclerosis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 122, 211-230.	1.0	17
138	Fulminant Demyelinating Diseases of the Central Nervous System. <i>Seminars in Neurology</i> , 2015, 35, 656-666.	0.5	17
139	Cerebral Gray Matter Atrophy Is Associated with the CSF IgG index in African American with Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2017, 27, 476-480.	1.0	17
140	Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 346-356.	1.7	17
141	Cell type-specific transcriptomics identifies neddylation as a novel therapeutic target in multiple sclerosis. <i>Brain</i> , 2021, 144, 450-461.	3.7	16
142	AQP4-IgG-seronegative patient outcomes in the N-MOMentum trial of inebilizumab in neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103356.	0.9	16
143	Multiple sclerosis: two decades of progress. <i>Lancet Neurology</i> , The, 2022, 21, 211-214.	4.9	16
144	Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1526-1540.	1.4	16

#	ARTICLE	IF	CITATIONS
145	Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5â€%years of follow-up in the DAYBREAK open-label extension trial. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1944-1962.	1.4	16
146	Polygenic risk score association with multiple sclerosis susceptibility and phenotype in Europeans. <i>Brain</i> , 2023, 146, 645-656.	3.7	15
147	Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS. <i>American Journal of Neuroradiology</i> , 2020, 41, 2219-2226.	1.2	14
148	Retinal <scp>INL</scp> Thickness in Multiple Sclerosis: A Mere Marker of Neurodegeneration?. <i>Annals of Neurology</i> , 2021, 89, 192-193.	2.8	14
149	Detection of Neoplasms by Metagenomic Next-Generation Sequencing of Cerebrospinal Fluid. <i>JAMA Neurology</i> , 2021, 78, 1355.	4.5	14
150	Specific hypomethylation programs underpin B cell activation in early multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	14
151	Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis. <i>JAMA Neurology</i> , 2013, 70, 248.	4.5	13
152	Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 752.	0.9	13
153	Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 103010.	0.9	13
154	Characterizing retinal structure injury in African-Americans with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 7, 16-20.	0.9	12
155	Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. <i>European Journal of Neurology</i> , 2021, 28, 3722-3730.	1.7	12
156	Steering through complexity. <i>Current Opinion in Neurology</i> , 2016, 29, 263-271.	1.8	11
157	Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 48.	4.5	11
158	Sensitivity analysis of the primary endpoint from the N-MOMentum study of inebilizumab in NMOSD. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2052-2061.	1.4	11
159	Cryptococcal Meningitis Reported With Fingolimod Treatment. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	11
160	Does race matter for multiple sclerosis?. <i>Neurology</i> , 2010, 74, 532-533.	1.5	10
161	Placebo controlled trials in neuromyelitis optica are needed and ethical. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 536-545.	0.9	10
162	Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 50-56.	0.9	9

#	ARTICLE	IF	CITATIONS
163	An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1432-1441.	1.4	9
164	Effects of COVID-19 “Sheltering in Place” on Activity in People With Multiple Sclerosis. <i>Neurology: Clinical Practice</i> , 2021, 11, e216-e218.	0.8	8
165	Lymphocyte counts and infection rates. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	3.1	7
166	Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2219-2231.	1.4	7
167	Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. <i>Journal of Neurology</i> , 2022, 269, 5093-5104.	1.8	7
168	DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS OF MULTIPLE SCLEROSIS. CONTINUUM Lifelong Learning in <i>Neurology</i> , 2010, 16, 19-36.	0.4	5
169	Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis “ Commentary. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1161-1162.	1.4	5
170	Imaging correlates of visual function in multiple sclerosis. <i>PLoS ONE</i> , 2020, 15, e0235615.	1.1	5
171	Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102695.	0.9	5
172	Identifying falls remotely in people with multiple sclerosis. <i>Journal of Neurology</i> , 2022, 269, 1889-1898.	1.8	5
173	A hormonal therapy for menopausal women with MS: A phase Ib/IIa randomized controlled trial. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103747.	0.9	5
174	Mycophenolate Mofetil to Treat Neuromyelitis Optica. <i>JAMA Neurology</i> , 2014, 71, 1354.	4.5	4
175	Simultaneous serum aquaporin-4 antibody and CSF NMDA receptor antibody “positive encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e101.	3.1	4
176	Acute liver injury in a Glatopa-treated patient with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e368.	3.1	4
177	Making Every Step Count: Minute-by-Minute Characterization of Step Counts Augments Remote Activity Monitoring in People With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	4
178	Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder”. <i>Neurology and Therapy</i> , 2022, 11, 1439-1443.	1.4	4
179	2014 Multiple Sclerosis Therapeutic Update. <i>Neurohospitalist, The</i> , 2014, 4, 63-65.	0.3	3
180	Statistical Considerations for an Adaptive Design for a Serious Rare Disease. <i>Therapeutic Innovation and Regulatory Science</i> , 2016, 50, 375-384.	0.8	3

#	ARTICLE	IF	CITATIONS
181	The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731881924.	0.5	3
182	Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2022, 62, 103793.	0.9	3
183	Patient preferences for attributes of disease modifying Therapies: Results of a choice based conjoint analysis. Value in Health, 2013, 16, A107.	0.1	2
184	Reply to "Silent Progression or Bout Onset Progressive Multiple Sclerosis?". Annals of Neurology, 2019, 86, 472-473.	2.8	2
185	Is TOPIC the last trial for clinically isolated syndrome?. Nature Reviews Neurology, 2015, 11, 6-7.	4.9	1
186	Switching to fingolimod in PREFERMS: Effect of treatment history and naïveté on clinical, MRI and treatment satisfaction outcomes. Multiple Sclerosis and Related Disorders, 2020, 45, 102346.	0.9	1
187	Interferon Beta-1a Treatment and African Americans"Reply. Archives of Neurology, 2006, 63, 628.	4.9	0
188	F.36. Introduction of a Cell-based Assay Against Native Aquaporin-4-High Specificity and Sensitivity for Neuromyelitis Optica. Clinical Immunology, 2008, 127, S54-S55.	1.4	0
189	Is there a role for planned natalizumab dosage suspension in mitigating progressive multifocal leukoencephalopathy risk?. Neurodegenerative Disease Management, 2011, 1, 11-14.	1.2	0
190	Diagnosing Encephalitis, Not Otherwise Specified"Reply. JAMA Neurology, 2015, 72, 726.	4.5	0
191	Longer-term Safety with Siponimod Treatment in Multiple Sclerosis: Pooled Analysis of Data from the Bold and Expand Trials and their Extensions. Multiple Sclerosis and Related Disorders, 2018, 26, 255-256.	0.9	0
192	Multiple Sclerosis Therapy: Are We Ready for a One-Size-Fits-All Approach?. Journal of Neuro-Ophthalmology, 2018, 38, 258-262.	0.4	0
193	Author response: Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology, 2019, 92, 151.2-151.	1.5	0
194	Multiple Sclerosis Genetics. , 2018, , .		0
195	Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS". Annals of Neurology, 2022, 91, 735-736.	2.8	0
196	Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615.		0
197	Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615.		0
198	Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615.		0

#	ARTICLE	IF	CITATIONS
199	Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615.		0